Bavarian aims for universal Covid-19 booster

Bavarian Nordic is betting on its vaccine candidate providing broad protection, and imminent trial results could indicate where the booster has potential.

Photo: Philip Davali/Ekstra Bladet, Philip Davali

In February, Bavarian Nordic will have the next round of results ready from a trial of its Covid-19 vaccine candidate. According to the company’s CEO, Paul Chaplin, the vaccine will be universal in its protection, as reported by Danish business daily Børsen.

”With the success that boosters have had, and the flattening of Omicron’s curve, we don’t need an Omicron specific vaccine. The vaccines designed against the strain found in Wuhan, and which are mRNA based, are adequate to prevent a serious infection,” Chaplin tells Børsen

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Rumored GN purchase unlikely but not impossible, say analysts

A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.

New CFO wants to shake things up at WSA

A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.

Further reading

Related articles

Latest news

See all jobs